BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 32089544)

  • 1. Androgen receptor with short polyglutamine tract preferably enhances Wnt/β-catenin-mediated prostatic tumorigenesis.
    He Y; Mi J; Olson A; Aldahl J; Hooker E; Yu EJ; Le V; Lee DH; Kim WK; Robins DM; Geradts J; Sun Z
    Oncogene; 2020 Apr; 39(16):3276-3291. PubMed ID: 32089544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen signaling is a confounding factor for β-catenin-mediated prostate tumorigenesis.
    Lee SH; Luong R; Johnson DT; Cunha GR; Rivina L; Gonzalgo ML; Sun Z
    Oncogene; 2016 Feb; 35(6):702-14. PubMed ID: 25893287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant activation of hepatocyte growth factor/MET signaling promotes β-catenin-mediated prostatic tumorigenesis.
    Aldahl J; Mi J; Pineda A; Kim WK; Olson A; Hooker E; He Y; Yu EJ; Le V; Lee DH; Geradts J; Sun Z
    J Biol Chem; 2020 Jan; 295(2):631-644. PubMed ID: 31819003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor (AR) suppresses normal human prostate epithelial cell proliferation via AR/β-catenin/TCF-4 complex inhibition of c-MYC transcription.
    Antony L; van der Schoor F; Dalrymple SL; Isaacs JT
    Prostate; 2014 Aug; 74(11):1118-31. PubMed ID: 24913829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased Akt signaling resulting from the loss of androgen responsiveness in prostate cancer.
    Dulinska-Litewka J; McCubrey JA; Laidler P
    Curr Med Chem; 2013; 20(1):144-57. PubMed ID: 23033951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens.
    Schweizer L; Rizzo CA; Spires TE; Platero JS; Wu Q; Lin TA; Gottardis MM; Attar RM
    BMC Cell Biol; 2008 Jan; 9():4. PubMed ID: 18218096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant androgen action in prostatic progenitor cells induces oncogenesis and tumor development through IGF1 and Wnt axes.
    Kim WK; Olson AW; Mi J; Wang J; Lee DH; Le V; Hiroto A; Aldahl J; Nenninger CH; Buckley AJ; Cardiff R; You S; Sun Z
    Nat Commun; 2022 Jul; 13(1):4364. PubMed ID: 35902588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ZMIZ1 preferably enhances the transcriptional activity of androgen receptor with short polyglutamine tract.
    Li X; Zhu C; Tu WH; Yang N; Qin H; Sun Z
    PLoS One; 2011; 6(9):e25040. PubMed ID: 21949845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of β-Catenin Cooperates with Loss of Pten to Drive AR-Independent Castration-Resistant Prostate Cancer.
    Patel R; Brzezinska EA; Repiscak P; Ahmad I; Mui E; Gao M; Blomme A; Harle V; Tan EH; Malviya G; Mrowinska A; Loveridge CJ; Rushworth LK; Edwards J; Ntala C; Nixon C; Hedley A; Mackay G; Tardito S; Sansom OJ; Leung HY
    Cancer Res; 2020 Feb; 80(3):576-590. PubMed ID: 31719098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of the tumor suppressor, Tp53, enhances the androgen receptor-mediated oncogenic transformation and tumor development in the mouse prostate.
    He Y; Johnson DT; Yang JS; Wu H; You S; Yoon J; Lee DH; Kim WK; Aldahl J; Le V; Hooker E; Yu EJ; Geradts J; Cardiff RD; Sun Z
    Oncogene; 2019 Sep; 38(38):6507-6520. PubMed ID: 31358900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-182 promotes prostate cancer progression through activating Wnt/β-catenin signal pathway.
    Wang D; Lu G; Shao Y; Xu D
    Biomed Pharmacother; 2018 Mar; 99():334-339. PubMed ID: 29353209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling.
    Song H; Yu Z; Sun X; Feng J; Yu Q; Khan H; Zhu X; Huang L; Li M; Mok MTS; Cheng ASL; Gao Y; Feng H
    EBioMedicine; 2018 Sep; 35():155-166. PubMed ID: 30150059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capn4 expression is modulated by microRNA-520b and exerts an oncogenic role in prostate cancer cells by promoting Wnt/β-catenin signaling.
    Ren W; Wang D; Li C; Shu T; Zhang W; Fu X
    Biomed Pharmacother; 2018 Dec; 108():467-475. PubMed ID: 30241050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secreted Frizzled-related protein-1 is a negative regulator of androgen receptor activity in prostate cancer.
    Kawano Y; Diez S; Uysal-Onganer P; Darrington RS; Waxman J; Kypta RM
    Br J Cancer; 2009 Apr; 100(7):1165-74. PubMed ID: 19277043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The beta-catenin binding protein ICAT modulates androgen receptor activity.
    Zhuo M; Zhu C; Sun J; Weis WI; Sun Z
    Mol Endocrinol; 2011 Oct; 25(10):1677-88. PubMed ID: 21885566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p68/DdX5 supports β-catenin & RNAP II during androgen receptor mediated transcription in prostate cancer.
    Clark EL; Hadjimichael C; Temperley R; Barnard A; Fuller-Pace FV; Robson CN
    PLoS One; 2013; 8(1):e54150. PubMed ID: 23349811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer.
    Wang G; Wang J; Sadar MD
    Cancer Res; 2008 Dec; 68(23):9918-27. PubMed ID: 19047173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis.
    Chesire DR; Ewing CM; Gage WR; Isaacs WB
    Oncogene; 2002 Apr; 21(17):2679-94. PubMed ID: 11965541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of androgen receptor and β-catenin activity in prostate cancer.
    Lee E; Madar A; David G; Garabedian MJ; Dasgupta R; Logan SK
    Proc Natl Acad Sci U S A; 2013 Sep; 110(39):15710-5. PubMed ID: 24019458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of WNT/beta-catenin pathway activation on signaling through T-cell factor and androgen receptor in prostate cancer cell lines.
    Cronauer MV; Schulz WA; Ackermann R; Burchardt M
    Int J Oncol; 2005 Apr; 26(4):1033-40. PubMed ID: 15753999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.